

Remarks

Original claims 1-37 are canceled without prejudice to pursue these claims in continuation and/or divisional applications. New claims 38-63 are added. The newly added claims are fully supported in the specification as filed and do not add new matter.

The Examiner previously rejected then-pending claims 1-30 and 32-25 under 35 U.S.C. 112, first paragraph, and claims 2, 6-7 and 14 under 35 U.S.C. 112, second paragraph. The Examiner also found that the then pending claims 1-30 and 32-35 were free of prior art.

The newly added claims are directed to methods of treating Ig-E related disease or modulating IgE levels in a patient by administration of a defined class of molecules. Thus, the newly added claims are believed to obviate the prior section 112 rejections.

Applicant respectfully requests withdrawal of all rejections and allowance of all claims.

Respectfully submitted,



Karen L. Nicastro
Attorney for Applicants
Registration No.: 35,968
Phone: (805) 447-7211
Date: November 20, 2002

Please send all future correspondence to:

US Patent Operations/ KLN
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799